$7.69
-0.38-4.71%
Last update: Nov 10, 4:00 PM
Regenxbio Inc
RGNXNASDAQ
Regenxbio fell 26.8% from $11.02 to $8.07, behind the S&P 500's +10.0%. Its worst day was May 14 (−37.8%), and its low came May 18 at $5.65.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Regenxbio closed at its highest level of the year, 45.0% above where the year started.
+6.4% · S&P 500 +0.5%
EPS of $-1.30 missed the $-0.91 estimate on $30.3M revenue (est. $39.9M).
Story events cover the past 12 months · Times ET
−4.6% · S&P 500 −0.6%
EPS of $-1.72 missed the $-1.40 estimate on $6.4M revenue (est. $25.0M).
−37.8%, the year's worst day, on 10M shares, the year's heaviest volume · S&P 500 +0.8%
Regenxbio shares rose 16.3%, while the S&P 500 fell 0.3%.
+16.3% · S&P 500 −0.3%
EPS of $0.43 beat the $0.12 estimate on $108.0M revenue (est. $104.1M).
+7.4% · S&P 500 −0.2%
Regenxbio shares fell 24.9%, while the S&P 500 fell 0.3%.
−24.9% · S&P 500 −0.3%
EPS of $-0.62 beat the $-1.31 estimate on $9.2M revenue (est. $10.5M).
−4.3% · S&P 500 −4.4%
Where it ended: a close of $8.07 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 4, 2027 (EPS est. $-1.44, revenue est. $51.0M).
Nothing in the past 12 months.
All RGNX dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RGNX and SPY from Benzinga historical bars. Not investment advice.
